GlassScriptPhysician profile
Jahnavi Chakrala
NPI 1003237934
$594.73
in general payments reported to CMS, 2019-2025
11 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.69 · 2023: $343 · 2024: $103 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $193.98 | 2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $90.66 | 2023-2025 | Omnipod |
| Novo Nordisk INC | $81.75 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $61.98 | 2024-2025 | Minimed 780g |
| Amgen INC. | $58.41 | 2023-2025 | Tepezza, Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $22.43 | 2023 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $20.17 | 2023 | |
| Amryt Pharma Holdings LTD | $18.11 | 2023 | Mycapssa |
| Shire North American Group INC | $16.62 | 2019 | |
| Abbvie INC. | $16.55 | 2025 | |
| Medtronic Minimed, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jahnavi Chakrala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.